(News Bulletin 247) – Oddo BHF maintains its ‘outperform’ rating on Novartis shares, with an unchanged price target of 105 Swiss francs, as Novartis announces the acquisition of Chinook Therapeutics, an American biotech at the clinical stage, for a total amount of $3.5 billion.
Oddo BHF reports that this acquisition will enable Novartis to strengthen its late-stage pipeline in rare kidney diseases with atrasentan (in phase 3, topline results expected in Q4) and zigakibart (entering phase 3).
‘The company’s rerating could continue through quarterly publications, the ramp-up of products in the launch phase (Leqvio, Pluvicto, Scemblix) as well as the publication of clinical results expected in the next 24 months (iptacopan , pelacarsen, ianalumab, remibrutinib, etc.)’, concludes the broker.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
